Atragen injectable all-trans retinoic acid regulatory update

ARNX said the FDA's Oncologic Drugs Advisory Committee withdrew its invitation to review on Sept. 17 ARNX's NDA for Atragen to treat acute promyelocytic leukemia (APL). The FDA cited deficiencies in ...